
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is performing well with its leading position in the TMS market and a strong commercial model, shown through an 83.5% PTSD response rate and a 52% reduction in PCL-5scores in a recent study. With additional evidence supporting its Deep TMS as a versatile technology for various psychiatric and neurological conditions, BrainsWay has a promising pipeline for future growth. While some risks such as inconsistent execution and regulatory delays remain, the potential for additional indications and revenue streams makes BrainsWay a solid investment opportunity.
Bears say
BrainsWay is an established player in the noninvasive neurostimulation market, with a strong focus on recurring revenue and partnerships with mental health clinic networks. With a growing target market and potential for international expansion, the company is primed for continued revenue growth. In addition, recent financial results have exceeded expectations and suggest operational efficiency, leading to a positive buy rating from analysts and a raised price target of $19 per share.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares